Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Free Access

Treatment of Cyclothymic Disorder: Commentary

Baldessarini R.J.a, b · Vázquez G.b, c · Tondo L.b, d

Author affiliations

aDepartment of Psychiatry, Harvard Medical School and Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, Mass., and bInternational Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, Mass., USA; cDepartment of Neuroscience, University of Palermo, Buenos Aires, Argentina; dLucio Bino Mood Disorders Center, Cagliari, Italy

Corresponding Author

Dr. Ross Baldessarini

Mailman Research Center 312

McLean Hospital, 115 Mill Street

Belmont, MA 02467-9106 (USA)

Tel. +1 617 855 3203, Fax +1 617 855 3479, E-Mail rjb@mclean.org

Related Articles for ""

Psychother Psychosom 2011;80:131–135

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.

First-Page Preview
Abstract of Editorial


  1. Fava GA, Rafanelli C, Tomba E, Guidi J, Grandi S: The sequential combination of cognitive behavioral treatment and well-being therapy in cyclothymic disorder. Psychother Psychosom 2011;80:136–143.
  2. da Costa RT, Rangé BP, Malagris LE, Sardinha A, de Carvalho MR, Nardi AE: Cognitive-behavioral therapy for bipolar disorder. Expert Rev Neurother 2010;10:1089–1099.
  3. Fava GA, Tomba E: Increasing psychological well-being and resilience by psychotherapeutic methods. J Pers 2009;77:1903–1934.
  4. Westermeyer J: Major depressive disorder with subthreshold bipolarity: exploring and managing new diagnoses. Am J Psychiatry 2010;167:1145–1147.
  5. Howland RH, Thase ME: Comprehensive review of cyclothymic disorder. J Nerv Ment Dis 1993;181:485–493.
  6. Baethge C, Salvatore P, Baldessarini RJ: On cyclic insanity (1882) by Karl Ludwig Kahlbaum, MD: translation and commentary. Harv Rev Psychiatry 2003;11:78–90.
  7. Baethge C, Baldessarini RJ: Cyclothymia, a circular mood disorder (1893), classic text 55 by Ewald Hecker (translation). Hist Psychiatry 2003;14:391–399.
    External Resources
  8. Trede K, Salvatore P, Baethge C, Gerhard A, Maggini C, Baldessarini RJ: Manic-depressive illness: evolution in Kraepelin’s textbook, 1883–1926. Harv Rev Psychiatry 2005;13:155–178.
  9. World Health Organization (WHO): International Classification of Diseases, Tenth Edition (ICD-10). Geneva, WHO, 1990.
  10. American Psychiatric Association (APA): Diagnostic and Statistical Manual, Fourth revision (DSM-IV). Washington, American Psychiatric Press, 1994.
  11. Goodwin FK, Jamison KR: Manic-Depressive Illness, ed 2. New York, Oxford University Press, 2007, pp 82–86.
  12. Perugi G, Toni C, Maremmani I, Tusini G, Ramacciotti S, Madia A, Fornaro M, Akiskal HS: Influence of affective temperaments and psychopathological traits on the definition of bipolar disorder subtypes: study on bipolar I Italian national sample. J Affect Disord 2010, E-pub ahead of print.
  13. Vázquez GH, Tondo L, Mazzarini L, Gonda X: Affective temperaments in general population: review and combined analysis from national studies. J Affect Disord, in press.
  14. Mazzarini L, Pacchiarotti I, Colom F, Sani G, Kotzalidis GD, Rosa AR, Sanna L, De Rossi P, Girardi N, Bonnin CM, Sanchez-Moreno J, Vázquez GH, Gasto C, Tatarelli R, Vieta E: Predominant polarity and temperament in bipolar and unipolar affective disorders. J Affect Disord 2009;119:28–33.
  15. Vázquez GH, Kahn V, Schiavo CE, Goldchluk A, Herbst L, Piccione M, Saidman N, Ruggeri H, Silva A, Leal J, Bonetto GG, Zaratiegui R, Padilla E, Vilaprino JJ, Calvó M, Guerrero G, Strejilevich SA, Cetkovich-Bakmas MG, Akiskal KK, Akiskal HS: Bipolar disorders and affective temperaments: national family study testing the ‘endophenotype’ and ‘subaffective’ theses using the TEMPS-A Buenos Aires. J Affect Disord 2008;108:25–32.
  16. Kilzieh N, Akiskal HS: Rapid-cycling bipolar disorder: overview of research and clinical experience. Psychiatr Clin North Am 1999;22:585–607.
  17. Hajek T, Hahn M, Slaney C, Garnham J, Green J, Růzicková M, Zvolský P, Alda M: Rapid cycling bipolar disorders in primary and tertiary care treated patients. Bipolar Disord 2008;10:495–502.
  18. Lee S, Tsang A, Kessler RC, Jin R, Sampson N, Andrade L, Karam EG, Mora ME, Merikangas K, Nakane Y, Popovici DG, Posada-Villa J, Sagar R, Wells JE, Zarkov Z, Petukhova M: Rapid-cycling bipolar disorder: cross-national community study. Br J Psychiatry 2010;196:217–225.
  19. Akiskal HS: Subaffective disorders: dysthymic, cyclothymic and bipolar II disorders in the ‘borderline’ realm. Psychiatr Clin North Am 1981;4:25–46.
  20. Hantouche EG, Akiskal HS: Toward a definition of a cyclothymic behavioral endophenotype: which traits tap the familiar diathesis for bipolar II disorder? J Affect Disord 2006;96:223–237.
  21. Kochman FJ, Hantouche EG, Ferrari P, Lancrenon S, Bayert D, Akiskal HA: Cyclothymic temperament as a prospective predictor of bipolarity and suicidality in children and adolescents with major depressive disorder. J Affect Disord 2005;85:181–189.
  22. Skjelstad DV, Malt UF, Holte A: Symptoms and signs of the initial prodrome of bipolar disorder: systematic review. J Affect Disord 2010;126:1–13.
  23. Akiskal HS, Akiskal KK, Haykal RF, Manning JS, Connor PD: TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord 2005;85:3–16.
  24. Tondo L, Vázquez G, Baldessarini RJ: Mania associated with antidepressant-treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010;121:404–414.
  25. Amsterdam JD, Shults J: Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010;167:792–800.
  26. Swartz HA, Thase ME: Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2010, E-pub ahead of print.
  27. Bisol LW, Lara DR: Low-dose quetiapine for patients with dysregulation of hyperthymic and cyclothymic temperaments. J Psychopharmacol 2001;24:421–424.
    External Resources
  28. Montes JM, Saiz-Ruiz J, Lahera G, Asiel A: Lamotrigine for the treatment of bipolar spectrum disorder: chart review. J Affect Disord 2005;86:69–73.
  29. Vieta E: Defining the bipolar spectrum and treating bipolar II disorder. J Clin Psychiatry 2008;69:e12–e17.
  30. Calabrese JR: Overview of patient care issues and treatment in bipolar spectrum and bipolar II disorder. J Clin Psychiatry 2008;69:e18–e23.
  31. Huxley NA, Parikh SV, Baldessarini RJ: Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry 2000;8:126–140.
  32. Shen GH, Sylvia LG, Allloy LB, Barrett F, Kohner M, Iacoviello B, Mills A: Lifestyle regularity and cyclothymic symptomatology. J Clin Psychol 2008;64:482–500.
  33. Totterdell P, Kellett S: Restructuring mood in cyclothymia using cognitive behavioral therapy: intensive time-sampling study. J Clin Psychol 2008;64:501–518.
  34. Miklowitz DJ, Scott J: Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions. Bipolar Disord 2009;11(suppl 2): 110–122.
  35. Colom F, Vieta E, Sánchez-Moreno J, Goikolea JM, Popova E, Bonnin CM, Scott J: Psychoeducation for bipolar II disorder: an exploratory, 5-year outcome subanalysis. J Affect Disord 2009;112:30–35.

Article / Publication Details

Received: October 20, 2010
Accepted: October 23, 2010
Published online: March 03, 2011
Issue release date: April 2011

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 1

ISSN: 0033-3190 (Print)
eISSN: 1423-0348 (Online)

For additional information: https://www.karger.com/PPS

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.